Drug
Plitidepsin clinical trials
- studies test it
- 16
- open now
- 0
- in phase 3
- 2
- first study started
- 2004
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 2
PharmaMar (14) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Institut Bergonié (1)
Often tested with
Tested in the same studies.
Bortezomib (2) · Dexamethasone (2) · Sorafenib (1) · Gemcitabine (1) · Cytarabine (1)
Studies
Open first, then newest update. How each study uses plitidepsin is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)CompletedPhase 2Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT06766825Written as Plitidepsin 1.5 mg/day
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as Plitidepsin
- Extension Study in a Cohort of Adult Patients With COVID-19 InfectionCompletedPhase 1/2PharmaMarNCT05121740Written as Plitidepsin 1.5 mg / day
- Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)TerminatedPhase 2PharmaMarNCT05705167Written as Plitidepsin
- Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19CompletedPhase 1PharmaMarNCT04382066Written as Plitidepsin 1.5 mg/day
- Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialTerminatedPhase 2Institut BergoniéNCT01876043Written as plitidepsin
- Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedPhase 2PharmaMarNCT03117361Written as plitidepsin
- A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate CancerTerminatedPhase 2PharmaMarNCT00780975Written as Aplidin (plitidepsin)
- Aplidin - Dexamethasone in Relapsed/Refractory MyelomaCompletedPhase 3PharmaMarNCT01102426Written as Plitidepsin
- A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaTerminatedPhase 2PharmaMarNCT03070964Written as plitidepsin
- Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedPhase 1PharmaMarNCT02100657Written as Plitidepsin
- Clinical Trial of Aplidin® in Patients With Primary MyelofibrosisCompletedPhase 2PharmaMarNCT01149681Written as APLIDIN (plitidepsin)
- Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory LeukemiaTerminatedPhase 1/2PharmaMarNCT00780143Written as Plitidepsin plus Cytarabine
- Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin LymphomaCompletedPhase 2PharmaMarNCT00884286Written as Aplidin®
- Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or LymphomasCompletedPhase 1PharmaMarNCT00788099Written as Plitidepsin and Sorafenib
- A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaCompletedPhase 2PharmaMarNCT00229203Written as Plitidepsin
Codes
What other systems call plitidepsin · ClinicalTrials.gg INT003897
- MeSH (NLM) C098980plitidepsinOne source NLM
- UNII (FDA) Y76ID234HWPLITIDEPSINConfirmed FDA, NLM
- NCI Thesaurus C1689PlitidepsinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C098980 | plitidepsin | One source NLM |
| UNII (FDA) | Y76ID234HW | PLITIDEPSIN | Confirmed FDA, NLM |
| NCI Thesaurus | C1689 | Plitidepsin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.